2024

• de Luca Montes, R., Golder, V., Lateef, A., Navarra, S., Zamora, L., Hamijoyo, L., Sockalingam, S., An, Y., Li, Z., Katsumata, Y., Nikpour, M., et al (2024). Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study. Advances in Rheumatology, 64(1), 38. [More Information]
• Bhullar, H., Wada, M., Nikpour, M., Saracino, A. (2024). Atypical morphoea, a herald of two malignancies: Lung adenocarcinoma and a neuroendocrine tumour. Journal of Scleroderma and Related Disorders. [More Information]
• Fairley, J., O'Rourke, R., Puranik, R., Nikpour, M. (2024). Cardiac magnetic resonance imaging in systemic sclerosis: Heart involvement in high-resolution. Rheumatology and Immunology Research, 5(2), 83-92. [More Information]
• Huang, V., Ciciriello, S., Nikpour, M., Oon, S., Day, J. (2024). Diagnosing and characterizing inflammatory myopathies at an Australian tertiary public hospital: Resource utilization and direct healthcare costs. International Journal of Rheumatic Diseases, 27(4), e15153. [More Information]
• Hao, Y., Oon, S., Nikpour, M. (2024). Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 67, 152465. [More Information]
• Fairley, J., Ross, L., Nikpour, M. (2024). Heart involvement in systemic sclerosis: emerging concepts. Current Opinion In Rheumatology, , 1038. [More Information]
• Fairley, J., Stevens, W., Nikpour, M., Ross, L., Hansen, D., Baron, M., Proudman, S., Sahhar, J., Ngian, G., Walker, J., et al (2024). Investigating the trajectory of functional disability in systemic sclerosis: group-based trajectory modelling of the Health Assessment Questionnaire-Disability Index. Clinical and Experimental Rheumatology, 42(8), 1581-1589. [More Information]
• Parker, M., Jee, A., Hansen, D., Proudman, S., Youssef, P., Kenna, T., Stevens, W., Nikpour, M., Sahhar, J., Corte, T. (2024). Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis. Rheumatology, 63(11), 2981-2988. [More Information]
• Nielsen, W., Navarra, S., Aranow, C., MacKay, M., Trotter, K., Tayer-Shifman, O., Duarte-Garcia, A., Shan Tam, L., Ugarte-Gil, M., PonsEstel, G., Nikpour, M., et al (2024). OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set. Seminars in Arthritis and Rheumatism, 65, 152380. [More Information]
• Nielsen, W., Bruce, I., Parodis, I., Kim, A., Desai, M., Enman, Y., Shea, B., Wallace, D., Chaichian, Y., Navarra, S., Nikpour, M., et al (2024). OMERACT systemic lupus erythematosus domain survey. Seminars in Arthritis and Rheumatism, 68, 152520. [More Information]
• Fairley, J., Burns, A., Morrisroe, K., Stevens, W., Nikpour, M., Ross, L., Hansen, D., Proudman, S., Sahhar, J., Ngian, G., et al (2024). Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosis. Seminars in Arthritis and Rheumatism, 66, 152443. [More Information]
• Fairley, J., Stevens, W., Ross, L., Nikpour, M., Hansen, D., Day, J., Proudman, S., Sahhar, J., Ngian, G., Walker, J., et al (2024). Proximal weakness and creatine kinase elevation in systemic sclerosis: Clinical correlates, prognosis and functional implications. Seminars in Arthritis and Rheumatism, 65, 152363. [More Information]
• Katsumata, Y., Chen, Y., Luo, S., Wu, Y., Hamijoyo, L., Li, Z., Sockalingam, S., Navarra, S., Zamora, L., Hao, Y., Nikpour, M., et al (2024). Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Annals of the Rheumatic Diseases, , ard-2023-225369. [More Information]
• Yeo, A., Kandane-Rathnayake, R., Koelmeyer, R., Golder, V., Louthrenoo, W., Chen, Y., Cho, J., Lateef, A., Hamijoyo, L., Luo, S., Nikpour, M. (2024). SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus-an analysis of anti-double-stranded DNA monitoring. Rheumatology, 63(2), 525-533. [More Information]
• Williamson, L., Hao, Y., Basnayake, C., Oon, S., Nikpour, M. (2024). Systematic review of treatments for the gastrointestinal manifestations of systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 69, 152567. [More Information]
• Fairley, J., Stevens, W., Ross, L., Nikpour, M., Hansen, D., Proudman, S., Baron, M., Sahhar, J., Ngian, G., Walker, J., et al (2024). The burden and determinants of fatigue in incident and prevalent systemic sclerosis. Clinical and Experimental Rheumatology, 42(8), 1669-1674. [More Information]
• Ross, L., Host, L., Nikpour, M., Proudman, S., Hansen, D., Maltez, N., Morrisroe, K., Kumar, K., Walker, J., Stevens, W., et al (2024). The effect of calcium channel blockers on digital ulcers in systemic sclerosis: data from a prospective cohort study. Clinical Rheumatology, 43(1), 269-276. [More Information]
• Quinlivan, A., Ngian, G., Apostolopoulos, D., Host, L., Major, G., Basnayake, C., Morrisroe, K., Nikpour, M., Neuen, D., Hansen, D., et al (2024). The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes. Arthritis Research and Therapy, 26(1), 124. [More Information]

2023

• Jee, A., Stewart, I., Youssef, P., Adelstein, S., Lai, D., Hua, S., Stevens, W., Proudman, S., Ngian, G., Glaspole, I., Corte, T., et al (2023). A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis–Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study. Arthritis & Rheumatology, 75(8), 1424-1433. [More Information]
• Connelly, K., Kandane-Rathnayake, R., Hoi, A., Louthrenoo, W., Hamijoyo, L., Luo, S., Wu, Y., Cho, J., Lateef, A., Lau, C., et al (2023). Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study. Arthritis & Rheumatology, 75(3), 401-410. [More Information]
• Fairley, J., Hansen, D., Ross, L., Proudman, S., Sahhar, J., Ngian, G., Walker, J., Host, L., Morrisroe, K., Apostolopoulous, D., et al (2023). Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis. Arthritis Research and Therapy, 25(1). [More Information]
• Ross, L., Nikpour, M. (2023). Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials. Current Opinion In Rheumatology, 35(6), 334-340. [More Information]
• Ross, L., Costello, B., Lindqvist, A., Hansen, D., Brown, Z., Stevens, W., Burns, A., Prior, D., Pianta, M., Perera, W., et al (2023). Disease specific determinants of cardiopulmonary fitness in systemic sclerosis. Seminars in Arthritis and Rheumatism, 58. [More Information]
• Cho, J., Shen, L., Huq, M., Kandane-Rathnayake, R., Golder, V., Louthrenoo, W., Chen, Y., Hamijoyo, L., Luo, S., Wu, Y., et al (2023). Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study. The Lancet Rheumatology, 5(10), e584-e593. [More Information]
• Fairley, J., Ross, L., Burns, A., Prior, D., Conron, M., Rouse, H., McDonald, J., MacIsaac, A., La Gerche, A., Morrisroe, K., et al (2023). Multidisciplinary team discussion: the emerging gold standard for management of cardiopulmonary complications of connective tissue disease. Internal Medicine Journal, 53(10), 1919-1924. [More Information]
• Baron, M., Barbacki, A., Man, A., De Vries-Bouwstra, J., Johnson, D., Stevens, W., Osman, M., Wang, M., Zhang, Y., Proudman, S., et al (2023). Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling. Rheumatology, 62(9), 3059-3066. [More Information]
• Fairley, J., Ross, L., Quinlivan, A., Hansen, D., Paratz, E., Stevens, W., Kistler, P., McLellan, A., La Gerche, A., Nikpour, M. (2023). Sudden cardiac death, arrhythmias and abnormal electrocardiography in systemic sclerosis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 62, 152229. [More Information]
• Fairley, J., Goh, N., Nikpour, M. (2023). Systemic sclerosis-associated interstitial lung disease: Diagnostic approaches and challenges. Revista Colombiana de Reumatologia (Print Edition). [More Information]
• Smith, R., Harrison, M., Lam, K., Adler, B., Bulsara, M., Sahhar, J., Stevens, W., Proudman, S., Nikpour, M., Gabbay, E. (2023). The emerging association between bronchiectasis and systemic sclerosis: assessing prevalence and potential causality. Internal Medicine Journal, 53(7), 1204-1211. [More Information]
• Conley, B., Bunzli, S., Bullen, J., O’Brien, P., Persaud, J., Gunatillake, T., Dowsey, M., Choong, P., Nikpour, M., Grainger, R., et al (2023). What are the core recommendations for gout management in first line and specialist care? Systematic review of clinical practice guidelines. BMC Rheumatology, 7(1). [More Information]
• Conley, B., Bunzli, S., Bullen, J., O’Brien, P., Persaud, J., Gunatillake, T., Nikpour, M., Grainger, R., Barnabe, C., Lin, I. (2023). What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. Clinical Rheumatology, 42(9), 2267-2278. [More Information]

2022

• Sreedharan, S., Li, N., Littlejohn, G., Buchanan, R., Nikpour, M., Morand, E., Hoi, A., Golder, V. (2022). Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study. Arthritis Research and Therapy, 24(1). [More Information]
• Zheng, B., Wang, M., Stevens, W., Proudman, S., Nikpour, M., Baron, M. (2022). Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures. Seminars in Arthritis and Rheumatism, 53. [More Information]
• Hanson, A., Sahhar, J., Ngian, G., Roddy, J., Walker, J., Stevens, W., Nikpour, M., Assassi, S., Proudman, S., Mayes, M., et al (2022). Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes. Frontiers in Genetics, 13. [More Information]
• Ross, L., Costello, B., Brown, Z., Hansen, D., Lindqvist, A., Stevens, W., Burns, A., Prior, D., Nikpour, M., La Gerche, A. (2022). Myocardial fibrosis and arrhythmic burden in systemic sclerosis. Rheumatology, 61(11), 4497-4502. [More Information]
• Villanueva-Martin, G., Acosta-Herrera, M., Kerick, M., López-Isac, E., Simeón, C., Callejas, J., Assassi, S., Beretta, L., Allanore, Y., Proudman, S., et al (2022). The Effect of Body Fat Distribution on Systemic Sclerosis. Journal of Clinical Medicine, 11(20). [More Information]

2021

• Kandane-Rathnayake, R., Louthrenoo, W., Golder, V., Luo, S., Wu, Y., Lateef, A., Cho, J., Li, Z., An, Y., Hamijoyo, L., et al (2021). Independent associations of lymphopenia andneutropenia in patients with systemic lupuserythematosus: a longitudinal, multinationalstudy. Rheumatology, 60(11), 5185?5193. [More Information]
• Oon, S., Nikpour, M. (2021). Metrics and Outcomes of SLE Clinical Trials. Outcome Measures and Metrics in Systemic Lupus Erythematosus, (pp. 371-390). United Kingdom: Springer International Publishing. [More Information]
• Brown, Z., Proudman, S., Morrisroe, K., Stevens, W., Hansen, D., Nikpour, M. (2021). Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. Seminars in Arthritis and Rheumatism, 51(3), 495-512. [More Information]

2020

• Morrisroe, K., Nikpour, M. (2020). Cancer and scleroderma: Recent insights. Current Opinion In Rheumatology, 32(6), 479-487. [More Information]
• Koelmeyer, R., Nim, H., Nikpour, M., Sun, Y., Kao, A., Guenther, O., Morand, E., Hoi, A. (2020). High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. Lupus Science and Medicine, 7(1). [More Information]
• Nikpour, M., Saracino, A. (2020). Hydroxychloroquine in dermatology: New perspectives on an old drug. Australasian Journal of Dermatology, 61(2), e150-e157. [More Information]
• Morrisroe, K., Hansen, D., Huq, M., Stevens, W., Sahhar, J., Ngian, G., Ferdowsi, N., Hill, C., Roddy, J., Walker, J., et al (2020). Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis. Arthritis Care and Research, 72(11), 1625-1635. [More Information]
• Yeo, A., Koelmeyer, R., Kandane-Rathnayake, R., Golder, V., Hoi, A., Huq, M., Hammond, E., Nab, H., Nikpour, M., Morand, E. (2020). Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 72(9), 1289-1295. [More Information]
• Ross, L., Stevens, W., Wilson, M., Huq, M., Strickland, G., Walker, J., Sahhar, J., Ngian, G., Roddy, J., Youssef, P., et al (2020). Performance of the 2017 EUSTAR activity index in an scleroderma cohort. Clinical Rheumatology, 39(12), 3701-3705. [More Information]
• Morrisroe, K., Stevens, W., Sahhar, J., Ngian, G., Ferdowsi, N., Hansen, D., Patel, S., Hill, C., Roddy, J., Walker, J., et al (2020). The clinical and economic burden of systemic sclerosis related interstitial lung disease. Rheumatology, 59(8), 1878-1888. [More Information]

2019

• Ferdowsi, N., Stevens, W., Baron, M., Nikpour, M. (2019). Damage indices in rheumatic diseases: A systematic review of the literature. Seminars in Arthritis and Rheumatism, 49(1), 27-34. [More Information]
• Ross, L., Prior, D., Proudman, S., Vacca, A., Baron, M., Nikpour, M. (2019). Defining primary systemic sclerosis heart involvement: A scoping literature review. Seminars in Arthritis and Rheumatism, 48(5), 874-887. [More Information]
• Ferdowsi, N., Huq, M., Stevens, W., Hudson, M., Wang, M., Tay, T., Burchell, J., Mancuso, S., Rabusa, C., Sundararajan, V., et al (2019). Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): A novel instrument to quantify organ damage in systemic sclerosis. Annals of the Rheumatic Diseases, 78(6), 807-816. [More Information]
• Morrisroe, K., Stevens, W., Sahhar, J., Ngian, G., Ferdowsi, N., Hill, C., Roddy, J., Walker, J., Proudman, S., Nikpour, M. (2019). Digital ulcers in systemic sclerosis: Their epidemiology, clinical characteristics, and associated clinical and economic burden. Arthritis Research and Therapy, 21(1). [More Information]
• Szawlowski, S., Choong, P., Li, J., Nelson, E., Nikpour, M., Scott, A., Sundararajan, V., Dowsey, M. (2019). How do surgeons' trade-off between patient outcomes and risk of complications in total knee arthroplasty? a discrete choice experiment in Australia. BMJ Open, 9(7). [More Information]
• Metwally, M., Thabet, K., Bayoumi, A., Nikpour, M., Stevens, W., Sahhar, J., Zochling, J., Roddy, J., Tymms, K., Strickland, G., Liddle, C., Manolios, N., George, J., Eslam, M., et al (2019). IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Scientific Reports, 9(1), 1-5. [More Information]
• Moxey, J., Huq, M., Proudman, S., Sahhar, J., Ngian, G., Walker, J., Strickland, G., Wilson, M., Ross, L., Major, G., et al (2019). Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. Arthritis Research and Therapy, 21(1). [More Information]

2018

• Samudra, A., Dwyer, K., Selan, C., Freddi, S., Murray-Segal, L., Nikpour, M., Hickey, M., Peter, K., Robson, S., Sashindranath, M., et al (2018). CD39 and CD73 activity are protective in a mouse model of antiphospholipid antibody-induced miscarriages. Journal of Autoimmunity, 88, 131-138. [More Information]
• Morrisroe, K., Hudson, M., Baron, M., De Vries-Bouwstra, J., Carreira, P., Wuttge, D., Wang, M., Frech, T., Stevens, W., Proudman, S., et al (2018). Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. Clinical and Experimental Rheumatology, 36, S53-S60.
• Connelly, K., Kandane-Rathnayake, R., Huq, M., Hoi, A., Nikpour, M., Morand, E. (2018). Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. Scientific Reports, 8(1). [More Information]
• Pauling, J., Frech, T., Hughes, M., Gordon, J., Domsic, R., Anderson, M., Ingegnoli, F., McHugh, N., Johnson, S., Hudson, M., et al (2018). Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis: A SCTC vascular working group report. Journal of Scleroderma and Related Disorders, 3(3), 249-252. [More Information]
• Ross, L., Stevens, W., Rabusa, C., Wilson, M., Ferdowsi, N., Walker, J., Sahhar, J., Ngian, G., Zochling, J., Roddy, J., et al (2018). The role of inflammatory markers in assessment of disease activity in systemic sclerosis. Clinical and Experimental Rheumatology, 36, S126-S134.

2017

• Otero, C., Assassi, S., Hudson, M., Mayes, M., Estrada-Y-Martin, R., Pedroza, C., Mills, T., Walker, J., Baron, M., Stevens, W., et al (2017). Antifibrillarin antibodies are associated with native north American ethnicity and poorer survival in systemic sclerosis. Journal of Rheumatology, 44(6), 799-805. [More Information]
• Golder, V., Kandane-Rathnayake, R., Hoi, A., Huq, M., Louthrenoo, W., An, Y., Li, Z., Luo, S., Sockalingam, S., Lau, C., et al (2017). Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Research and Therapy, 19(1), 62. [More Information]
• Host, L., Nikpour, M., Calderone, A., Cannell, P., Roddy, J. (2017). Autologous stem cell transplantation in systemic sclerosis: A systematic review. Clinical and Experimental Rheumatology, 35, S198-S207.
• Golder, V., Huq, M., Franklyn, K., Calderone, A., Lateef, A., Lau, C., Lee, A., Navarra, S., Godfrey, T., Oon, S., et al (2017). Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. Seminars in Arthritis and Rheumatism, 46(6), 798-803. [More Information]
• Morrisroe, K., Stevens, W., Sahhar, J., Ngian, G., Rabusa, C., Ferdowsi, N., Hill, C., Proudman, S., Nikpour, M. (2017). Quantifying the direct public health care cost of systemic sclerosis. Medicine, 96(48). [More Information]
• Morrisroe, K., Stevens, W., Huq, M., Prior, D., Sahhar, J., Ngian, G., Celermajer, D., Zochling, J., Proudman, S., Nikpour, M. (2017). Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Research and Therapy, 19(1), 1-10. [More Information]
• Morrisroe, K., Stevens, W., Huq, M., Sahhar, J., Ngian, G., Zochling, J., Roddy, J., Proudman, S., Nikpour, M., Nash, P. (2017). Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2(3), 188-195. [More Information]
• Morrisroe, K., Stevens, W., Huq, M., Sahhar, J., Ngian, G., Zochling, J., Roddy, J., Proudman, S., Nikpour, M., Hill, C., et al (2017). Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 35, S130-S137.

2016

• Connelly, K., Kandane-Rathnayake, R., Hoi, A., Nikpour, M., Morand, E. (2016). Association of MIF, but not type i interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. Scientific Reports, 6. [More Information]
• Dowsey, M., Nikpour, M., Dieppe, P., Choong, P. (2016). Associations between pre-operative radiographic osteoarthritis severity and pain and function after total hip replacement: Radiographic OA severity predicts function after THR. Clinical Rheumatology, 35(1), 183-189. [More Information]
• Franklyn, K., Lau, C., Navarra, S., Louthrenoo, W., Lateef, A., Hamijoyo, L., Wahono, C., Chen, S., Jin, O., Morton, S., et al (2016). Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Annals of the Rheumatic Diseases, 75(9), 1615-1621. [More Information]
• Morrisroe, K., Huq, M., Stevens, W., Rabusa, C., Proudman, S., Nikpour, M. (2016). Determinants of unemployment amongst Australian systemic sclerosis patients: Results from a multicentre cohort study. Clinical and Experimental Rheumatology, 34, 79-84.
• Golder, V., Kandane-Rathnayake, R., Hoi, A., Huq, M., Louthrenoo, W., An, Y., Li, Z., Luo, S., Sockalingam, S., Lau, C., et al (2016). Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Research and Therapy, 18(1), 260. [More Information]
• Apostolopoulos, D., Kandane-Rathnayake, R., Hoi, A., Nikpour, M., Morand, E. (2016). Independent association of glucocorticoids with damage accrual in SLE. Lupus Science and Medicine, 3(1). [More Information]
• Nikpour, M., Prior, D., Celermajer, D. (2016). Letter by Nikpour et al regarding article, "Effect of warfarin treatment on survival of patients with Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)". Circulation, 133(20), e661. [More Information]
• Owen, C., Ngain, G., Elford, K., Moore, O., Stevens, W., Nikpour, M., Rabusa, C., Proudman, S., Roddy, J., Youssef, P., et al (2016). Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clinical and Experimental Rheumatology, 34(Suppl. 100), S170-S176.
• Dowsey, M., Scott, A., Nelson, E., Li, J., Sundararajan, V., Nikpour, M., Choong, P. (2016). Using discrete choice experiments as a decision aid in total knee arthroplasty: Study protocol for a randomised controlled trial. Trials, 17(1). [More Information]

2015

• Yap, K., Northcott, M., Hoi, A., Morand, E., Nikpour, M. (2015). Association of low Vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. Lupus Science and Medicine, 2(1). [More Information]
• Patterson, K., Roberts-Thomson, P., Lester, S., Tan, J., Hakendorf, P., Rischmueller, M., Zochling, J., Sahhar, J., Nash, P., Roddy, J., et al (2015). Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis. Arthritis & Rheumatology, 67(12), 3234-3244. [More Information]

2014

• Nikpour, M., Bridge, J., Richter, S. (2014). A systematic review of prevalence, disease characteristics and management of systemic lupus erythematosus in Australia: Identifying areas of unmet need. Internal Medicine Journal, 44(12), 1170-1179. [More Information]
• Vacca, A., Meune, C., Gordon, J., Chung, L., Proudman, S., Assassi, S., Nikpour, M., Rodriguez-Reyna, T., Khanna, D., Lafyatis, R., et al (2014). Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology, 53(7), 1172-1177. [More Information]
• Nikpour, M., Baron, M. (2014). Mortality in systemic sclerosis: Lessons learned from population-based and observational cohort studies. Current Opinion In Rheumatology, 26(2), 131-137. [More Information]
• Dowsey, M., Nikpour, M., Choong, P. (2014). Outcomes following large joint arthroplasty: Does socio-economic status matter? BMC Musculoskeletal Disorders, 15(1). [More Information]
• Morrisroe, K., Stevens, W., Nandurkar, H., Prior, D., Thakkar, V., Roddy, J., Zochling, J., Sahhar, J., Tymms, K., Sturgess, A., et al (2014). The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis. Clinical and Experimental Rheumatology, 32(6).
• Franklyn, K., Hoi, A., Nikpour, M., Morand, E. (2014). The need to define treatment goals for systemic lupus erythematosus. Nature Reviews Rheumatology, 10(9), 567-571. [More Information]

2013

• Nikpour, M., Gladman, D., Ibañez, D., Harvey, P., Urowitz, M. (2013). Assessment of coronary risk based on cumulative exposure to lipids in systemic lupus erythematosus. Journal of Rheumatology, 40(12), 2006-2014. [More Information]
• Touma, Z., Gladman, D., MacKinnon, A., Carette, S., Abu-Shakra, M., Askanase, A., Nived, O., Hanly, J., Landolt-Marticorena, C., Tam, L., et al (2013). Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website. Journal of Rheumatology, 40(1), 34-39. [More Information]
• Nikpour, M. (2013). Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? Lupus, 22(12), 1243-1250. [More Information]
• Nikpour, M., Stevens, W., Proudman, S., Buchbinder, R., Prior, D., Zochling, J., Williams, T., Gabbay, E., Nandurkar, H. (2013). Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated? Internal Medicine Journal, 43(5), 599-603. [More Information]

2012

• Dowsey, M., Nikpour, M., Dieppe, P., Choong, P. (2012). Associations between pre-operative radiographic changes and outcomes after total knee joint replacement for osteoarthritis. Osteoarthritis and Cartilage, 20(10), 1095-1102. [More Information]
• Nikpour, M., Harvey, P., Ibañez, D., Gladman, D., Urowitz, M. (2012). High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. Arthritis & Rheumatology, 64(9), 3052-3053. [More Information]
• Ngian, G., Stevens, W., Prior, D., Gabbay, E., Roddy, J., Tran, A., Minson, R., Hill, C., Chow, K., Sahhar, J., et al (2012). Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Research and Therapy, 14(5). [More Information]

2011

• Nikpour, M., Urowitz, M., Ibañez, D., Harvey, P., Gladman, D. (2011). Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: A prospective proof-of-concept cohort study. Arthritis Research and Therapy, 13(5). [More Information]
• Ibañez, D., Gladman, D., Touma, Z., Nikpour, M., Urowitz, M. (2011). Optimal frequency of visits for patients with Systemic Lupus Erythematosus to measure Disease Activity over time. Journal of Rheumatology, 38(1), 60-63. [More Information]
• Nikpour, M., Hissaria, P., Byron, J., Sahhar, J., Micallef, M., Paspaliaris, W., Roddy, J., Nash, P., Sturgess, A., Proudman, S., et al (2011). Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: A cross-sectional analysis of data from an Australian cohort. Arthritis Research and Therapy, 13(6). [More Information]
• Nikpour, M., Urowitz, M., Ibañez, D., Gladman, D. (2011). Relationship between cardiac symptoms, myocardial perfusion defects and coronary angiography findings in systemic lupus erythematosus. Lupus, 20(3), 299-304. [More Information]

2010

• Nikpour, M., Stevens, W., Herrick, A., Proudman, S. (2010). Epidemiology of systemic sclerosis. Best Practice & Research: Clinical Rheumatology, 24(6), 857-869. [More Information]
• Nikpour, M., Proudman, S., Goh, N., Moutsopoulos, H. (2010). Interstitial lung disease in Sjogren's syndrome. Current Rheumatology Reviews, 6(2), 127-137. [More Information]
• Nikpour, M., Gladman, D., Ibañez, D., Harvey, P., Urowitz, M. (2010). Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: A longitudinal cohort study. Arthritis Research and Therapy, 12(3). [More Information]

2009

• Nikpour, M., Urowitz, M., Ibañez, D., Gladman, D. (2009). Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Care and Research, 61(9), 1152-1158. [More Information]
• Nikpour, M., Gladman, D., Ibañez, D., Bruce, I., Burns, R., Urowitz, M. (2009). Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. Journal of Rheumatology, 36(2), 288-294. [More Information]
• Goldberg, R., Urowitz, M., Ibañez, D., Nikpour, M., Gladman, D. (2009). Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. Journal of Rheumatology, 36(11), 2454-2461. [More Information]
• Nikpour, M., Gladman, D., Ibañez, D., Urowitz, M. (2009). Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. Lupus, 18(11), 966-973. [More Information]

2008

• Nikpour, M., Dempsey, A., Urowitz, M., Gladman, D., Barnes, D. (2008). Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Annals of the Rheumatic Diseases, 67(8), 1069-1075. [More Information]

2007

• Osborne, R., Nikpour, M., Busija, L., Sundararajan, V., Wicks, I. (2007). Prevalence and cost of musculoskeletal disorders: A population-based, public hospital system healthcare consumption approach. Journal of Rheumatology, 34(12), 2466-2475.

2006

• Lee, A., Godfrey, T., Rowley, K., Karschimkus, C., Dragicevic, G., Romas, E., Clemens, L., Wilson, A., Nikpour, M., Prior, D., et al (2006). Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Internal Medicine Journal, 36(4), 237-243. [More Information]

2005

• Nikpour, M., Urowitz, M., Gladman, D. (2005). Premature atherosclerosis in systemic lupus erythematosus. Rheumatic Diseases Clinics of North America, 31(2), 329-354. [More Information]